Purification of Drug Loaded PLGA Nanoparticles Prepared by Emulsification Solvent Evaporation Using Stirred Cell Ultrafiltration Technique

PASWAN, SURESH K.; Saini, T. R.

doi:10.1007/s11095-017-2257-5

Cited by 28 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trace of PVA in the obtained NPs was determined using boric acid, as previously described. 47,48 The standard curve of PVA is shown in Figure S2. PVA was found to remain in NPs only 0.67% ± 0.05, suggesting the minimal of PVA adsorbed on the NP surface.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Payomhom,

Panyain,

Sakonsinsiri

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Ursolic acid (UA), a pentacyclic triterpenoid found in various fruits and herbs, has the potential as an anticancer agent against multiple cancer types. Nevertheless, its clinical use was limited by its poor water solubility. To overcome this drawback, several nanocarriers were proposed to increase the bioavailability and efficacy of UA. However, the insights into the cellular targets and mechanisms of UA and UA nanoparticles (NPs) remain limited. In this study, chitosan-coated poly(lactic-co-glycolic acid) (PLGA/CS) NPs were loaded with UA. The obtained (UA)-PLGA/CS NPs were spherical with an approximate size of 250 nm and an encapsulation efficiency of 25%. Owing to their promising potential as drug carriers, the NPs were successfully delivered into breast cancer cells (MCF-7 and MDA-MB-231). Moreover, (UA)-PLGA/CS NPs enhanced the anticancer activity of UA, as evidenced by the IC 50 values of 26.74 and 40.67 μM in MCF-7 and MDA-MB-231 cells, respectively. These values were lower than those of free UA (90.25 and 85.63 μM in MCF-7 and MDA-MB-231 cells, respectively). The improved cytotoxicity induced by (UA)-PLGA/CS NPs can be attributed to apoptosis induction, collective cell migration and invasion inhibition, and cell proliferation pathway disruption. These findings led to a better understanding of the anticancer effects and molecular mechanisms of (UA)-PLGA/CS NPs and their potential targets for breast cancer therapy.

show abstract

Section: ■ Results and Discussionmentioning

confidence: 99%

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Payomhom,

Panyain,

Sakonsinsiri

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…With the increase of PLGA concentration, the size of microcapsules decreased from several microns to several hundred nanometers. PLGA not only acted as a drug carrier but also played the role of an emulsifier when the internal water phase was encapsulated into the oil phase [ 30 – 32 ]. It could be inferred that the stability of the colostrum was one of the key factors affecting the EE of microcapsules.…”

Section: Discussionmentioning

confidence: 99%

Application of Implantable Polylactic-Co-Glycolic Acid Microcapsule in Repairing Alveolar Bone Defects

Jiang

Xiao

Wang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Alveolar bone defects (ABDs) were a perennial problem, especially in the aged. Bisphosphonates, especially etidronate sodium (ET), were frequently used in clinical treatment of ABD. However, the oral administration of ET had poor absorption (<1%). Therefore, optimization of a suitable dosage form substituted with ET to locally repair the ABD was a straightforward approach. Polylactide-co-glycolide (PLGA) is a biodegradable material and had been used in locally implanted medical devices. Therefore, an ET-PLGA microcapsule may help local delivery and prolong the activity of healing ABD. In this paper, a preparation method of ET-PLGA microcapsule was optimized by the single-factor investigation and response surface method. Subsequently, the rat ABD model was used to evaluate the enhancement effect of these microcapsules. Finally, the optimum parameters were determined as follows: 40% dichloromethane, 160 mg/mL PLGA, 10% internal aqua/oil phase, 4% PVA, and emulsifying for 10 min. These microcapsules were spherical in shape and fairly monodisperse in a particle size of 27,51 μm (PDI = 0.3), encapsulation rate 96.6%, and drug loading 4.58%. Compared with the ET groups, the total healing volume of ABD in ET-PLGA groups was significantly increased P < 0.05 . ET-PLGA microcapsules significantly enhanced the effect of ET on ABD. This study provided important technical support for the treatment of ABD with bisphosphonates by local administration. This paper has an exploratory significance for the development of water-soluble bioactive components with low bioavailability for ABD.

show abstract

“…Gef/Qur NPs were prepared from PLGA–PEG diblock copolymers by modified emulsification solvent evaporation method. 20 Briefly, the polymer (0.5 mg) and an appropriate amount of drug (Gef 5mg; Qur 5mg) were dissolved in ethyl acetate (5mL) to obtain a solution of 10% (w/v) PLGA–PEG, 1.0 mg/mL (w/v) Gef and 1.0 mg/mL (w/v) Qur, which was then added to a solution of 2.5% (w/v) poly(vinyl alcohol) (PVA). The mixture was then shaken vigorously and treated with sonication (200 Hz, 2min).…”

Section: Methodsmentioning

confidence: 99%

<p>Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells</p>

Shen

Tantai

2020

DDDT

View full text Add to dashboard Cite

Introduction This study aims to develop a novel co-delivery gefitinib and quercetin system loaded with PLGA-PEG nanoparticles and evaluate their antitumor activity in vitro and in vivo. Methods Gef/Qur NPs were prepared and characterized. The release of drugs, stability, cellular uptake and cytotoxicity were evaluated in vitro. The antitumor effects and systemic toxicity of different formulations were also investigated. Results Gef/Qur NPs displayed a smaller particle size and a PDI and zeta potential of 0.11 and −23.5 mV, respectively. The hydrophobic Gef and Qur content in NPs reached up to 65.2% and 56.4%, respectively, and their high entrapment efficiencies recorded 83.7% and 82.3%, respectively. The in vitro release of Gef/Qur from the NPs was sustained for 12 h. Compared with control groups, Gef/Qur NPs showed higher cellular uptake and cell inhibition rates. In vivo studies identified the lungs as the target tissue and the region of maximum drug release. Through pharmacodynamics analysis, we found that two drugs (Gef and Qur) were incorporated into one nanoparticle carrier, which played a good role in generating synergistic effect. Discussion It is concluded that PLGA-PEG is an ideal drug carrier for the co-delivery of Gef/Qur to treat lung cancer.

show abstract

Purification of Drug Loaded PLGA Nanoparticles Prepared by Emulsification Solvent Evaporation Using Stirred Cell Ultrafiltration Technique

Cited by 28 publications

References 19 publications

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Application of Implantable Polylactic-Co-Glycolic Acid Microcapsule in Repairing Alveolar Bone Defects

<p>Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells</p>

Contact Info

Product

Resources

About